Vraylar for depression augmentation

Vraylar (cariprazine) is an atypical antipsychotic that got an FDA add-on indication for major depression a few years back. It’s been on TV constantly, the ads with the unrealistic happy person who used to be sad and is now hiking through a sunlit field with her dog. The ads work, patients ask about it by name, and most of them shouldn’t be on it. Some of them should. The trick is sorting which is which without letting the marketing budget make the decision.

It’s a dopamine D3-preferring partial agonist, which is the pharmacology nerd part of the answer. Translated: it modulates the dopamine system in a way that’s a little different from the older atypicals (atypical antipsychotic, the newer-generation class that includes Abilify and Rexulti and Seroquel, used at low doses for depression augmentation and higher doses for psychotic disorders). The depression augmentation evidence is real but modest. It’s another tool in the box, not a miracle, regardless of what the actress in the field implies.

Where it actually fits

Augmentation, not monotherapy. You’re already on an antidepressant, you’re maybe 40 to 60 percent better, and you’re not getting all the way there. Add Vraylar at low doses (1.5mg, sometimes 3mg) and watch what happens over the next four to six weeks. That’s the use case. Anybody trying to use this as a standalone for major depression is misreading what the FDA actually approved it for.

The trials are mixed, with a couple of positive studies and at least one that came up flat, but on balance adding it to an SSRI (selective serotonin reuptake inhibitor, the standard first-line antidepressant class like Lexapro and Zoloft) or SNRI (serotonin-norepinephrine reuptake inhibitor, the broader cousin class like Effexor and Cymbalta) helps some patients a bit more than placebo does. The effect size is similar to what you get with Abilify or Rexulti as augmentation agents. None of these are home runs. They’re each a single in the right situation, which is honestly all you usually need at this point in the treatment algorithm.

The selling point for Vraylar over its direct competitors is mostly weight and sedation profile. Less weight gain on average than Abilify. Less sedation than Seroquel. More activation, which means some patients feel wired or restless, particularly early on, and which is the trade-off built into the drug.

What it costs

List price is around $1,400 a month. Insurance coverage is the hurdle, and the way it usually goes is the insurer wants you to fail Abilify first because Abilify is generic now and dirt cheap, often under $20 a month. Some plans will cover Vraylar after that fail. The manufacturer copay card helps for commercial insurance, getting most patients to under $20 a month if they qualify. Medicare and Medicaid are more complicated and require more paperwork.

If you don’t have insurance, this drug is not a realistic option for most patients. You’d be paying $1,400 a month for a benefit that, in the trials, is real but modest, roughly a handful of percentage points more response than placebo on top of the antidepressant you’re already taking. The math doesn’t pencil out unless cost is no object, and most patients aren’t in that position. Generic Abilify at the same price point is a much better choice for cash-pay patients.

What it feels like

The most common report early on is activation. Slight restlessness, slight wiredness, sometimes a kind of jaw-clenching tension that patients describe as feeling caffeinated even when they haven’t had coffee. Most of this settles in the first two to four weeks. If it doesn’t, the dose drops or we switch. Patients who can’t tolerate the activation in the first month usually can’t tolerate it at all, and pushing through past four weeks rarely fixes it.

Akathisia is the one to watch for. It’s an inner restlessness that can feel unbearable, where you literally cannot sit still, you pace, you can’t stop moving your legs. It’s a side effect of all dopamine-modulating medications, and Vraylar gets it somewhat more than some of its cousins. If you feel like you can’t be in your skin, call the prescriber. Don’t wait it out. Akathisia is the kind of side effect that can drive people to do things they would never otherwise do, and it doesn’t usually resolve by itself if it gets going.

Weight gain is usually modest. A few pounds for most patients. The metabolic profile is better than older antipsychotics but still real. If you’re already heavy or pre-diabetic, the prescriber should be monitoring glucose and lipids, and any prescriber who isn’t checking those labs is being careless.

The sexual side effects are usually minimal, which is a real advantage over SSRIs and one of the cleaner things to be able to tell a patient who’s been struggling with that on the SSRI alone.

What’s nice to hear about this one

For the right patient, Vraylar can do the thing that the patient came in trying to do, which was finish getting out of the depression instead of being permanently 60 percent of the way out. Say you’ve got a guy who’s been on Effexor at maximum dose for two years, mostly out of the depression, still flat, still feels like he’s watching his life from a distance. The wife has been patient about it but has started asking what’s actually wrong, which is the sign the patience is running out. Add Vraylar 1.5mg. Comes back at four weeks reporting he feels a little more there. Not dramatically. Just more there. He stays on it. Six months in his wife says he’s different in a way she can’t put her finger on but likes. He starts enjoying weekends again. Starts caring about his hobbies again, the guitars he’d stopped playing. He had some akathisia in the first month that got managed by going slower with the dose. Two years on the combination now. Whether the Vraylar made the difference or whether time made the difference, hard to say with certainty in any single patient. He thinks it did. The trials say there’s a real signal there. The honest answer is some of both, and the patient gets the benefit either way.

The selling point for Vraylar over its competitors is mostly the weight and sedation profile, less weight gain on average, less sedation, and more activation, which means some patients feel wired early on.

Where it doesn’t fit

Patients who haven’t really tried an antidepressant at an adequate dose for an adequate duration. We’re not augmenting nothing… if the patient never gave Lexapro a real run, the answer is to give Lexapro a real run first, not to layer an expensive add-on on top of an under-dosed first-line drug.

Patients with significant restless leg syndrome, a history of akathisia, or movement disorders. They’re going to have a bad time on this drug, and there are other augmentation options that don’t carry the same risk for that specific population.

Patients with metabolic syndrome who don’t need any more weight or glucose problems on the chart, especially when generic alternatives are available and the marginal benefit of Vraylar over Abilify is modest.

Patients who saw the TV ad and want it because the actress is smiling in a field. Most of them respond fine to a simpler conversation about what’s actually going on, what’s already been tried, and what the cheaper next step is. The commercial is built to land emotionally. The prescribing decision should land mathematically. Those are usually different.

On the autonomy piece

Patients who walk in asking for Vraylar by name aren’t wrong to want it, they just often haven’t actually exhausted the cheaper options first, and the conversation needs to start there. If a patient has tried two antidepressants at adequate doses, tried Abilify augmentation, didn’t tolerate it or didn’t respond, and wants to try Vraylar next, you get Vraylar. I’m not a gatekeeper, I’m an opinionated provider, not a parent. If a patient comes in on month two of his first SSRI and wants to add Vraylar because of the commercial, the honest take is that the SSRI hasn’t had a real trial yet and the augmentation conversation belongs at month three or four, not month two. Disapproving yes is the most pushback you’ll get from me, and the appointment isn’t mine. The choice is yours.

Bottom line

Vraylar is a reasonable third or fourth move when an antidepressant alone isn’t getting a patient over the line. It works for some. The pharmacology is interesting, the D3 preference is genuinely a little different from its competitors. The price is annoying. The TV marketing has driven a lot of inappropriate requests. Used in the right spot, after the cheaper augmentation options have been exhausted or ruled out, it does what it says on the label. Just not as cleanly as the commercial suggests. Nothing in psychiatry is as clean as the commercials suggest, which is its own quiet lesson worth absorbing before you start a new drug because the ad made you feel something.

Sources

1. Durgam S, Earley W, Guo H, et al, Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder, J Clin Psychiatry, 2016, 77(3):371-378. PMID 27046309.
2. Sachs GS, Yeung PP, Rekeda L, et al, Adjunctive cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study, Am J Psychiatry, 2023, 180(3):241-251. PMID 36789515.
3. Earley WR, Guo H, Németh G, et al, Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial, Psychopharmacol Bull, 2018, 48(4):62-80. PMID 30618475.
4. Davies P, Ijaz S, Williams CJ, et al, Pharmacological interventions for treatment-resistant depression in adults, Cochrane Database Syst Rev, 2019, 12:CD010557. CD010557.